Participating Companies

Endocyte, Inc.

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases.  Endocyte uses its proprietary drug conjugation technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents for personalized targeted therapies.  The company’s SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells.  This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone.  The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.  Endocyte owns or has rights to over 400 issued patents and patent applications worldwide covering our core technology, SMDCs and companion imaging agents.

Endocyte currently has two SMDCs in human clinical trials. EC1456, a second generation SMDC, targets the folate receptor with a super-potent drug payload, tubulysin. This drug has potential application in a number of cancer types and the initial development plan focuses on non-small cell lung cancer.  EC1169 targets a different receptor, prostate-specific membrane antigen, or PSMA, with the same drug payload – tubulysin. Endocyte is evaluating this drug in patients with advanced prostate cancer. 

Management meeting request - click here

Presenter - Mike A. Sherman, President and CEO

Mike A. Sherman was named Endocyte's President and CEO in 2016. He had served concurrently as Chief Operating Officer and Chief Financial Officer since 2014.  Prior to joining the company as CFO in 2006, Mr. Sherman was vice president of finance and strategic planning of Guidant Corporation, a cardiovascular device manufacturer acquired by medical device company Boston Scientific Corporation. Mr. Sherman holds a BA in economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth. He also serves on the Board of Directors at Mead Johnson Nutrition, and the Indianapolis Children’s Museum Board of Trustees.

 

CEO :
Mike Sherman

NASDAQ:
ECYT

Visit Endocyte, Inc. at
www.endocyte.com

Investor relations for Endocyte, Inc. can be reached here